The pharmacy benefit manager dropped Zepbound a year ago in favor of rival Wegovy — now both Lilly and Novo Nordisk drugs will be co-preferred options ...

CVS Caremark is adding Zepbound, Eli Lilly’s obesity drug, back to its commercial insurance plan formularies, more than a year after it stopped covering it in favor of Novo Nordisk’s Wegovy.

In a reversal from last year, CVS will begin covering Eli Lilly's Zepbound and Foundayo in its standard prescription plan, a win for GLP-1 patients.

Plaintiffs are going to court to challenge CVS Caremark’s decision to stop covering Zepbound, a weight-loss drug that is also used to treat sleep apnea. Plaintiff Martin Hamburger filed his lawsuit in ...

(CNN) — Last week, Tara Eacobacci had an appointment with her doctor that was devoted exclusively to the topic of health insurance. A major change to her prescription benefits meant the medication she ...

Add Yahoo as a preferred source to see more of our stories on Google. When Zepbound, Eli Lilly's highly anticipated weight loss drug, hit the market a year and a half ago, it marked a turning point ...

CVS Caremark will resume covering the weight loss drug Zepbound this year after it removed it from its list of covered ...

CVS Caremark, one of the nation's largest pharmacy benefit managers, recently announced a new partnership with the discount drug service GoodRx, aiming to lower out-of-pocket prescription costs for ...

"It is vitally important that cash-strapped Medicaid programs receive reimbursement for costs they incur that should have been paid for by other insurers," said Assistant Attorney General for the ...